Company profile

Zai Lab Limited

Pipeline16 assets

NiraparibPARP / Inhibitor / Oncology
Ovarian Cancer (1st line maintenance)ApprovedOvarian Cancer (Platinum sensitive relapsed maintenance)Approved
Tumor Treating FieldsOncology
Glioblastoma (GBM)ApprovedPancreatic Cancer (1st line)Phase 3 / Pivotal
RipretinibTKI / Oncology
Gastrointestinal Stromal Tumors (GIST) (4th line)Approved
RepotrectinibROS1 / TRK / Oncology
ROS1+ NSCLCApprovedNTRK+ solid tumorsApproved
Tisotumab vedotinTF / ADC / Oncology
Cervical Cancer (2nd line+ r/m)Phase 3 / PivotalCervical Cancer (1st line r/m, combo)Phase 2 / POC
Zocilurtatug pelitecanZL-1310 / Zoci / DLL3 / ADC / Oncology
ES-SCLCPhase 3 / PivotalOther NECsPhase 2 / POC
ZL-6201LRRC15 / ADC / Oncology
Sarcoma & CAF+ Solid TumorPhase 1
ZL-1311MUC17xCD3 / Oncology
GI TumorsPre-clinical
ZL-1222PD-1/IL-12 / Oncology
Solid TumorsPre-clinical
EfgartigimodFcRn / Immunology
Generalized Myasthenia Gravis (gMG)ApprovedChronic Inflammatory Demyelinating Polyneuropathy (CIDP)ApprovedMyositisPhase 3 / Pivotal
PovetaciceptBAFF/APRIL / Immunology
IgA NephropathyPhase 3 / PivotalPrimary Membranous NephropathyPhase 2 / POC
ElegrobartIGF-1R / Immunology
TEDPhase 3 / Pivotal
ZL-1503IL13/IL31R / Immunology
Mod-to-Sev ADPhase 1
Xanomeline-TrospiumKarXT / Neuroscience
SchizophreniaApproved
OmadacyclineInfectious Disease
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)ApprovedCommunity-Acquired Bacterial Pneumonia (CABP)Approved
Sulbactam-DurlobactamInfectious Disease
HABP/VABP caused by Susceptible Isolates of Acinetobacter Baumannii-calcoaceticus ComplexApproved

Latest news18 items

Sep 29, 2026

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Poster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin Data adds to body of evidence supporting zoci as a potential backbone antibody-drug conjugate in first-line combination regimens for ES-SCLC Investor

Presentation / Abstract • Phase 1ESMO poster presentation Mon, Oct 26, 2026, 12:00 PM CEST

Aug 17, 2026

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show

Trial Results • Phase 3Topline results Mon, Aug 17, 2026

Aug 6, 2026

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half of 2026 Global Phase 1 data for zocilurtatug pelitecan (zoci) in combination with a PD-L1 inhibitor in first-line SCLC

Presentation / Abstract • Phase 1

Aug 3, 2026

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

- NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need - U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for zoci in pulmonary NECs from the European Medicines Agency, reinforcing zoci’s first-in-class

Jul 22, 2026

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

- Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT) SHANGHAI & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 22, 2026-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its second quarter 2026 financial results and provide

Jun 16, 2026

Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

- European Medicines Agency’s Committee for Orphan Medicinal Products recognized zoci’s preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or refractory extensive-stage small cell lung cancer (SCLC) - SCLC is the most

Jun 8, 2026

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China - TIVDAK demonstrated a statistically significant overall survival benefit in the global Phase 3 innovaTV 301 clinical trial, including in the

Jun 3, 2026

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren’s disease indicate maintenance of response following switch to biweekly dosing Cross-indication analysis of efgartigimod data across rheumatology

Presentation / Abstract • Phase 2EULAR 2026 presentation Wed, Jun 3, 2026, 7:00 AM CEST

Jun 1, 2026

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA nephropathy

- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – BOSTON --(BUSINESS WIRE)--Jun. 1, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application

May 21, 2026

Zai Lab Announces Changes to Senior Leadership Team

SHANGHAI & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 21, 2026-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley,

May 11, 2026

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need - Preliminary clinical data recently presented at the AACR Annual Meeting suggest zoci has potential to be a first-in-class therapy for epNECs - Zoci NEC clinical program

May 8, 2026

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative Patients treated with VYVGART in the ADAPT SERON study experienced rapid,

May 7, 2026

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

– Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for VYVGART – Zocilurtatug pelitecan (zoci) delivered standout data at AACR 2026, with a

May 5, 2026

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

- REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved 50% and 54% proptosis responder rates (PRR) at week 24, respectively, versus 15% placebo, both highly statistically significant results (p 0.0001) - - Elegrobart Q4W

Trial Results • Phase 3

Apr 22, 2026

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

- Company to host conference call and webcast on May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT) SHANGHAI & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 22, 2026-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2026 financial results and provide recent

Apr 18, 2026

Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases

-Efficacy and safety data shared at IMMUNOLOGY2026 reinforce potential of ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Strong inhibition of both inflammatory and pruritic pathways over 112 days following a single dose of

Apr 17, 2026

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases; at 1.6 mg/kg dose, the confirmed iORR was 62.5% (10/16), including complete responses Encouraging

Presentation / Abstract • Phase 1

Apr 15, 2026

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). Phase Ib/II study will test the combination of obrixtamig, a DLL3/CD3 T‑cell engager, with Zai Lab’s